News

Osmetech has made the strategic decision to build its own direct sales force in the US with the objective of targeting key molecular diagnostic testing laboratories as well

XOMA has expanded its biodefense programs to include the development of a novel antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to

Laureate Pharma has entered into a development and manufacturing agreement with ZZ Biotech. As per the agreement, Laureate will produce activated protein C variant under cGMP conditions. Robert

Richter-Helm BioLogics has completed the modernisation of it´s GMP-production facility in Hannover. Richter-Helm produces recombinant proteins, plasmid DNA and vaccines for biopharmaceuticals. The company said that the production

Abbott’s COMPARE trial demonstrates that Xience V Everolimus Eluting Coronary Stent System has shown better outcomes in safety and efficacy measures compared to the Taxus Liberte Paclitaxel-Eluting Coronary

Nycomed is planning to build a plant to manufacture active pharmaceutical ingredients (APIs) and has already finished dosage forms for the Russian pharmaceutical market as well as the

Sandoz has completed acquisition of EBEWE Pharma’s specialty generic injectables business for $1.3 billion. The transaction offers Sandoz a complementary portfolio of differentiated generics, with more than 15

Athera Biotechnologies, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), and ALPCO, a company providing quality research immunoassays, have signed a

China Biologic Products (China Biologic) entered into a research and development agreement with the Institute of Blood Transfusion (IBT) on September 11, 2009, to strengthen the company’s research